ERS Genomics has signed a non-exclusive license agreement with Sai Life Sciences, an integrated Contract Research, Development, and Manufacturing Organisation (CRDMO).

The agreement grants Sai Life Sciences access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio for use in research and product development. Through this license, Sai Life Sciences can integrate precision genome editing capabilities into its discovery and development platforms, strengthening its ability to support global pharmaceutical and biotechnology partners across small molecule programs.

Building on this access, Sai Life Sciences can deploy CRISPR/Cas9-enabled models and workflows to help clients validate targets, screen compounds and generate decision-relevant biological insights earlier in discovery, complementing its biology, DMPK and pharmacology platforms.

Maneesh Pingle, President, Discovery, Sai Life Sciences, said, "As the industry moves toward more complex biological questions and novel therapeutic approaches, we are continually expanding our scientific capabilities to stay ahead. The addition of CRISPR-Cas9 to our discovery platform is another step in that journey, strengthening our ability to support clients as they pursue the next generation of medicines. Our agreement with ERS Genomics gives us access to foundational CRISPR-Cas9 technology that will further strengthen these capabilities and expand the ways in which we can support our clients across discovery and development."

CRISPR/Cas9 is a transformative genome editing technology that enables precise and efficient modification of DNA. As genome editing becomes increasingly embedded in drug discovery workflows, from target validation to cell line engineering, access to foundational Intellectual Property (IP) remains essential to ensure responsible deployment and long-term freedom to operate.

John E. Milad, Chief Executive Officer, ERS Genomics, said, "We are delighted to welcome Sai Life Sciences as a licensee. Sai Life Sciences' integrated discovery, development and manufacturing capabilities and its global base of innovator partners make it a strong addition to our growing network of CRISPR licensees. By securing access to our foundational CRISPR/Cas9 portfolio, Sai Life Sciences is well positioned to advance innovative research and development programmes with clarity and confidence."